Sanofi cleared to market Admelog mealtime insulin

Print Friendly, PDF & Email
PARIS — Sanofi has received Food and Drug Administration approval for Admelog, described as the first follow-on insulin lispro to help people with diabetes manage blood sugar levels at mealtime.

Sanofi said Monday that Admelog (insulin lispro injection, 100 units/ml) will be available in both vials and the SoloStar pen, which is the most-used disposable insulin pen platform in the United States. The Admelog clinical development program involved more than 1,000 adults with type 1 or type 2 diabetes, the company reported.

Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes. Complementing our existing insulin portfolio, Admelog will offer a more affordable option for those who require control of their blood sugar levels at mealtime,” stated Stefan Oelrich, executive vice President and head of global diabetes and cardiovascular at Sanofi. “The approval of Admelog is an important milestone for Sanofi in our mission to serve patients living with chronic diseases such as diabetes.”

Prescription Admelog is a fast-acting human insulin used to improve blood sugar control in adults with type 2 diabetes and adults and children ages 3 and older with type 1 diabetes.

Sanofi noted that Admelog is a rapid-acting insulin similar to Eli Lilly’s Humalog, another insulin lispro 100 units/ml currently approved in the U.S.

Admelog also was granted marketing authorization as a biosimilar, under the proprietary name Insulin lispro Sanofi, by the European Commission in July 2017, Sanofi added.



Comments are closed.